Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 187 articles:
HTML format

Single Articles

    August 2022
  1. JANPIPATKUL K, Panvongsa W, Worakitchanon W, Reungwetwattana T, et al
    Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression.
    Anticancer Res. 2022;42:3835-3844.
    PubMed     Abstract available

  2. LEE YC, Weng YS, Wang HY, Hsu FT, et al
    Magnolol Induces Apoptosis Through Extrinsic/intrinsic Pathways and Attenuates NF-kappaB/STAT3 Signaling in Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2022;42:3825-3833.
    PubMed     Abstract available

    July 2022
  3. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available

  4. SATO J, Nakano K, Shimizu T, Uchida M, et al
    Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Anticancer Res. 2022;42:3575-3582.
    PubMed     Abstract available

  5. KIM YJ, Hong SE, Jang SK, Park KS, et al
    Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition.
    Anticancer Res. 2022;42:3475-3481.
    PubMed     Abstract available

  6. WU MF, Chen LH, Hsia NY, Shen YC, et al
    Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese.
    Anticancer Res. 2022;42:3381-3387.
    PubMed     Abstract available

  7. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    PubMed     Abstract available

  8. SHAM NO, Zhao L, Zhu Z, Roy TM, et al
    Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.
    Anticancer Res. 2022;42:3275-3284.
    PubMed     Abstract available

    June 2022
  9. NAKAMURA R, Yoneyama S, Tobita R, Kurihara S, et al
    Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes.
    Anticancer Res. 2022;42:3159-3168.
    PubMed     Abstract available

  10. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    PubMed     Abstract available

  11. SATO J, Uchida M, Wakabayashi H, Shimizu T, et al
    Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
    Anticancer Res. 2022;42:3109-3116.
    PubMed     Abstract available

  12. SHAMAVONIAN R, Cheng E, Karpes JB, Barat S, et al
    Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
    Anticancer Res. 2022;42:2939-2944.
    PubMed     Abstract available

  13. HIROSHIMA Y, Tamaki Y, Sawada T, Ishida T, et al
    Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System.
    Anticancer Res. 2022;42:2989-2995.
    PubMed     Abstract available

  14. BOLLER D, Doepfner KT, Laurentiis A, Guerreiro AS, et al
    Republication: Targeting PI3KC2beta Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
    Anticancer Res. 2022;42:3217-3230.
    PubMed     Abstract available

  15. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Large Tumor Size and High Neutrophil-to-lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2022;42:3029-3034.
    PubMed     Abstract available

  16. TU CY, Chen HJ, Hsia TC, Fang HY, et al
    Adjuvant Concurrent Chemoradiotherapy Versus Adjuvant Chemotherapy Only in Locally Advanced Non-small-cell Lung Cancer With Involved Microscopic Resection Margin: A Population-based Cohort Study.
    Anticancer Res. 2022;42:3195-3201.
    PubMed     Abstract available

  17. KASHIWAGI K, Sato-Yazawa H, Ishii J, Kohno K, et al
    LXRbeta Activation Inhibits the Proliferation of Small-cell Lung Cancer Cells by Depleting Cellular Cholesterol.
    Anticancer Res. 2022;42:2923-2930.
    PubMed     Abstract available

  18. NAKAMURA M, Ishikawa H, Ohnishi K, Baba K, et al
    Proton Beam Therapy in Elderly Patients With cT1-3N0M0 Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2953-2960.
    PubMed     Abstract available

  19. NIEDER C, Aanes SG, Haukland EC
    Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer.
    Anticancer Res. 2022;42:3061-3066.
    PubMed     Abstract available

    May 2022
  20. SHIOZAWA T, Numata T, Tamura T, Endo T, et al
    Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2583-2590.
    PubMed     Abstract available

  21. WATANABE S, Yamazaki H, Kimoto T, Suzuki G, et al
    Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation.
    Anticancer Res. 2022;42:2701-2709.
    PubMed     Abstract available

  22. BASSANELLI M, Ramella S, Zeuli M, Ceribelli A, et al
    Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC.
    Anticancer Res. 2022;42:2241-2247.
    PubMed     Abstract available

    April 2022
  23. CHEN CH, Chang JW, Chang CF, Huang CY, et al
    Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.
    Anticancer Res. 2022;42:2145-2157.
    PubMed     Abstract available

  24. GLATZEL E, Werner EM, Bohnet S, Rades D, et al
    A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer.
    Anticancer Res. 2022;42:2029-2032.
    PubMed     Abstract available

  25. SVATON M, Bratova M, Koubkova L, Fischer O, et al
    Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
    Anticancer Res. 2022;42:1987-1995.
    PubMed     Abstract available

  26. RADES D, Glatzel E, Bohnet S, Schild SE, et al
    Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer.
    Anticancer Res. 2022;42:1973-1977.
    PubMed     Abstract available

    March 2022
  27. KIM MH, Choi CM, Lee SY, Park CK, et al
    First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Anticancer Res. 2022;42:1615-1622.
    PubMed     Abstract available

  28. SVATON M, Drosslerova M, Fischer O, Marel M, et al
    Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1563-1569.
    PubMed     Abstract available

  29. LI CH, Yang YC, Hsia TC, Shen TC, et al
    Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk.
    Anticancer Res. 2022;42:1229-1236.
    PubMed     Abstract available

  30. II H, Kasahara Y, Yamaguma H, Kageyama S, et al
    Administration of Gapmer-type Antisense Oligonucleotides Targeting gamma-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts.
    Anticancer Res. 2022;42:1221-1227.
    PubMed     Abstract available

  31. OTOSHI T, Nagano T, Park J, Hosomi K, et al
    The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1589-1598.
    PubMed     Abstract available

  32. YUMURA M, Nagano T, Jimbo N, Dokuni R, et al
    Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1289-1294.
    PubMed     Abstract available

    February 2022
  33. JOGIAT UM, Chu QS, Nagendran J, Laing B, et al
    Bilateral Lung Transplant for Treatment of Idiopathic Pulmonary Fibrosis With Undetected Lung Adenocarcinoma: A Case Report.
    Anticancer Res. 2022;42:1157-1160.
    PubMed     Abstract available

  34. TAKENAKA T, Tagawa T, Kohno M, Haratake N, et al
    Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1137-1142.
    PubMed     Abstract available

  35. HORIUCHI M, Oguri T, Kagawa Y, Sone K, et al
    Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1073-1079.
    PubMed     Abstract available

  36. TAKANO N, Seike M, Sugano T, Matsuda K, et al
    A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.
    Anticancer Res. 2022;42:709-722.
    PubMed     Abstract available

    January 2022
  37. MESSEHA SS, Nezami MA, Hager S, Soliman KFA, et al
    A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition.
    Anticancer Res. 2022;42:441-447.
    PubMed     Abstract available

  38. SAVARESE-BRENNER B, Heugl M, Rath B, Schweizer C, et al
    MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer.
    Anticancer Res. 2022;42:429-439.
    PubMed     Abstract available

  39. HAYASHI K, Suzuki O, Shiomi H, Nakai M, et al
    Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:321-327.
    PubMed     Abstract available

  40. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available

  41. YASUDA Y, Nagano T, Jimbo N, Kiriu T, et al
    Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma.
    Anticancer Res. 2022;42:271-277.
    PubMed     Abstract available

  42. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases.
    Anticancer Res. 2022;42:229-236.
    PubMed     Abstract available

    December 2021
  43. MUTO S, Inomata S, Yamaguchi H, Mine H, et al
    CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.
    Anticancer Res. 2021;41:6267-6272.
    PubMed     Abstract available

  44. PUTRI HE, Sritularak B, Chanvorachote P
    Pongamol Inhibits Epithelial to Mesenchymal Transition Through Suppression of FAK/Akt-mTOR Signaling.
    Anticancer Res. 2021;41:6147-6154.
    PubMed     Abstract available

    November 2021
  45. FUJIWARA M, Doi H, Igeta M, Suzuki H, et al
    Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5793-5802.
    PubMed     Abstract available

  46. SHIMODA Y, Yoshida T, Shirasawa M, Mizuno T, et al
    Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:5739-5747.
    PubMed     Abstract available

  47. SAITO T, Ohnishi K, Ishikawa H, Nakamura M, et al
    Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease.
    Anticancer Res. 2021;41:5635-5642.
    PubMed     Abstract available

  48. SKRICKOVA J, Pesek M, Opalka P, Koubkova L, et al
    Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5625-5634.
    PubMed     Abstract available

  49. VENCLICEK O, Skrickova J, Brat K, Fischer O, et al
    Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
    Anticancer Res. 2021;41:5549-5556.
    PubMed     Abstract available

  50. KURODA H, Masago K, Takahashi Y, Fujita S, et al
    Positive Correlation Between the Number of Circulating Tumor Cells in the Pulmonary Vein and Tumor Spread Through Air Spaces in Resected Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5499-5505.
    PubMed     Abstract available

  51. NOJIMA Y, Shimizu K, Saisho S, Maeda AI, et al
    Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5469-5475.
    PubMed     Abstract available

  52. LIAO WC, Huang CW, Hsia TC, Shen YC, et al
    Association of TIMP-2 Rs8179090 Genotypes With Lung Cancer Risk in Taiwan.
    Anticancer Res. 2021;41:5425-5430.
    PubMed     Abstract available

  53. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available

    October 2021
  54. MATSUBARA T, Hirai F, Yamaguchi M, Hamatake M, et al
    Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
    Anticancer Res. 2021;41:5157-5163.
    PubMed     Abstract available

  55. MITSUYA S, Tsuruoka K, Kanaoka K, Funamoto T, et al
    Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2021;41:5137-5145.
    PubMed     Abstract available

  56. HAMADA K, Yoshimura K, Hirasawa Y, Hosonuma M, et al
    Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
    Anticancer Res. 2021;41:4985-4993.
    PubMed     Abstract available

  57. SON KH, Kim MY, Shin JY, Kim JO, et al
    Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Anticancer Res. 2021;41:4807-4820.
    PubMed     Abstract available

  58. ARAKI K, Yamamuro N, Tomonobu N, Kumon H, et al
    REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma.
    Anticancer Res. 2021;41:4837-4855.
    PubMed     Abstract available

  59. VODICKA J, Skala M, Sebek J, Treska V, et al
    The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
    Anticancer Res. 2021;41:5117-5122.
    PubMed     Abstract available

  60. JANSSEN S, Overhoff D, Froelich MF, Schoenberg SO, et al
    Detectability of Lung Nodules in Ultra-low Dose CT.
    Anticancer Res. 2021;41:5053-5058.
    PubMed     Abstract available

  61. KINOSHITA H, Shimozato O, Ishii T, Kamoda H, et al
    The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
    Anticancer Res. 2021;41:4947-4955.
    PubMed     Abstract available

    September 2021
  62. SURAPANENI SK, Nottingham E, Mondal A, Patel N, et al
    Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:4215-4228.
    PubMed     Abstract available

  63. KIM SW, DO SI, Na K
    External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay.
    Anticancer Res. 2021;41:4609-4617.
    PubMed     Abstract available

  64. YOSHIDA D, Kusunoki T, Takayama Y, Kusano Y, et al
    Comparison of Dose Distribution Between VMAT-SBRT and Scanning Carbon-ion Radiotherapy for Early-stage NSCLC.
    Anticancer Res. 2021;41:4571-4575.
    PubMed     Abstract available

  65. MIRKA H, Ferda J, Krakorova G, Vodicka J, et al
    The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma.
    Anticancer Res. 2021;41:4479-4482.
    PubMed     Abstract available

  66. SUZUKI S, Yamamoto M, Sanomachi T, Togashi K, et al
    Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
    Anticancer Res. 2021;41:4321-4331.
    PubMed     Abstract available

    August 2021
  67. GIATROMANOLAKI A, Anestopoulos I, Panayiotidis MI, Mitrakas A, et al
    Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:3989-3995.
    PubMed     Abstract available

  68. LAFAUY P, Silapech A, Aksorn N, Sritularak B, et al
    Millettocalyxin B Inhibits Migratory Behavior of Lung Cancer Cells via Integrin alpha5 Suppression.
    Anticancer Res. 2021;41:3843-3849.
    PubMed     Abstract available

  69. OTSUKA T, Ueda K, Furukawa T, Koriyama C, et al
    Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma.
    Anticancer Res. 2021;41:3997-4004.
    PubMed     Abstract available

  70. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available

    July 2021
  71. SHIONOYA Y, Hirohashi Y, Takahashi H, Hashimoto M, et al
    Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Anticancer Res. 2021;41:3699-3706.
    PubMed     Abstract available

  72. ZAITSU J, Yamashita Y, Ishikawa A, Saito A, et al
    Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.
    Anticancer Res. 2021;41:3673-3682.
    PubMed     Abstract available

  73. JANG SK, Hong SE, Lee DH, Kim JY, et al
    Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer Res. 2021;41:3481-3487.
    PubMed     Abstract available

    June 2021
  74. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed     Abstract available

  75. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed     Abstract available

  76. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed     Abstract available

  77. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed     Abstract available

  78. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed     Abstract available

    May 2021
  79. MASUDA T, Wakabayashi YU, Nakashima T, Nishimura Y, et al
    Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
    Anticancer Res. 2021;41:2661-2667.
    PubMed     Abstract available

  80. OKIMOTO T, Tsubata Y, Tanino R, Nakao M, et al
    ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
    Anticancer Res. 2021;41:2653-2660.
    PubMed     Abstract available

  81. SUGIURA H, Miki Y, Iwabuchi E, Saito R, et al
    Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Anticancer Res. 2021;41:2371-2381.
    PubMed     Abstract available

  82. KREJCI D, Opalka P, Krejci J, Zemanova M, et al
    Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
    Anticancer Res. 2021;41:2597-2603.
    PubMed     Abstract available

  83. AOKI K, Nagatani Y, Noma K, Tsugawa T, et al
    Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.
    Anticancer Res. 2021;41:2575-2581.
    PubMed     Abstract available

  84. HISAKANE K, Seike M, Sugano T, Matsuda K, et al
    PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2021;41:2501-2509.
    PubMed     Abstract available

  85. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available

  86. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
    Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
    Anticancer Res. 2021;41:2217-2225.
    PubMed     Abstract available

    April 2021
  87. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed     Abstract available

  88. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed     Abstract available

  89. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed     Abstract available

  90. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed     Abstract available

  91. SVATON M, Blazek J, Krakorova G, Pesek M, et al
    Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Anticancer Res. 2021;41:2053-2058.
    PubMed     Abstract available

  92. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available

    March 2021
  93. IWASHITA K, Mizuno T, Kumazawa S, Imaizumi K, et al
    Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Anticancer Res. 2021;41:1707-1711.
    PubMed     Abstract available

  94. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports.
    Anticancer Res. 2021;41:1693-1699.
    PubMed     Abstract available

  95. HIRASHIMA T, Noda Y, Suzuki H, Nasu S, et al
    Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients.
    Anticancer Res. 2021;41:1655-1662.
    PubMed     Abstract available

  96. SATO Y, Iihara H, Kinomura M, Hirose C, et al
    Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
    Anticancer Res. 2021;41:1615-1620.
    PubMed     Abstract available

  97. DIMAKAKOS E, Livanios K, Vathiotis I, Gomatou G, et al
    Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2021;41:1523-1528.
    PubMed     Abstract available

  98. ITO N, Masuda T, Nakashima T, Nakao S, et al
    Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.
    Anticancer Res. 2021;41:1497-1506.
    PubMed     Abstract available

  99. CHEN WT, Chen CH, Su HT, Yueh PF, et al
    Amentoflavone Induces Cell-cycle Arrest, Apoptosis, and Invasion Inhibition in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2021;41:1357-1364.
    PubMed     Abstract available

  100. LEE HK, Noh MH, Hong SW, Kim SM, et al
    Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems.
    Anticancer Res. 2021;41:1261-1269.
    PubMed     Abstract available

  101. GRIESING S, Liao BC, Yang JC
    CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1231-1242.
    PubMed     Abstract available

  102. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  103. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed     Abstract available

  104. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

    February 2021
  105. AKAMATSU H, Ozawa Y, Oyanagi J, Fujimoto D, et al
    Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
    Anticancer Res. 2021;41:911-917.
    PubMed     Abstract available

  106. CLEVERS MR, Kastelijn EA, Peters BJM, Kelder H, et al
    Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:869-876.
    PubMed     Abstract available

  107. WEE CW, Kim JH, Kim HJ, Kang HC, et al
    Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.
    Anticancer Res. 2021;41:757-764.
    PubMed     Abstract available

  108. YAMAMOTO J, Aoki Y, Han Q, Sugisawa N, et al
    Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells.
    Anticancer Res. 2021;41:641-643.
    PubMed     Abstract available

  109. YAMASHITA N, Oyama T, So T, Miyata T, et al
    Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma.
    Anticancer Res. 2021;41:905-910.
    PubMed     Abstract available

  110. OSHIRO H, Tome Y, Miyake K, Higuchi T, et al
    A Novel Orthotopic Mouse Model of Lung Metastasis Using Fluorescent Patient-derived Osteosarcoma Cells.
    Anticancer Res. 2021;41:635-640.
    PubMed     Abstract available

    January 2021
  111. NIEDER C, Imingen KS, Mannsaker B, Yobuta R, et al
    Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
    Anticancer Res. 2021;41:355-358.
    PubMed     Abstract available

  112. LIU YC, Huang BH, Chung JG, Liu WL, et al
    Lenvatinib Inhibits AKT/NF-kappaB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:123-130.
    PubMed     Abstract available

  113. KAWABATA S, Connis N, Gills JJ, Hann CL, et al
    Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Anticancer Res. 2021;41:91-99.
    PubMed     Abstract available

    December 2020
  114. ASHI N, Kataoka Y, Takemura T, Shirakawa C, et al
    Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study.
    Anticancer Res. 2020;40:7141-7145.
    PubMed     Abstract available

  115. LIU B, Shiraga S, Mortenson MM, Lai J, et al
    Small Cell Lung Carcinoma and Synchronous Rectal Adenocarcinoma and Jejunal Gastrointestinal Stromal Tumor Present in a Patient With History of Laryngeal Squamous Cell Carcinoma.
    Anticancer Res. 2020;40:7053-7056.
    PubMed     Abstract available

  116. VODICKA J, Fichtl J, Sebek J, ProchAzkovA K, et al
    Outcomes and Prognostic Factors Following Surgical Treatment of Pulmonary Metastases from Colorectal Carcinoma.
    Anticancer Res. 2020;40:7045-7051.
    PubMed     Abstract available

  117. HIRASHIMA T, Kanai T, Suzuki H, Yoshida H, et al
    Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:6971-6978.
    PubMed     Abstract available

  118. MORIMOTO M, Nishino K, Wada K, Imamura F, et al
    Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Alphafter Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:6957-6970.
    PubMed     Abstract available

  119. YOON JH, Cho SG
    ADGRF4 Regulates Non-small Cell Lung Cancer Cell Invasiveness.
    Anticancer Res. 2020;40:6835-6844.
    PubMed     Abstract available

  120. WATANABE T, Sawabata N, Kawaguchi T, Yoshikawa D, et al
    Clustered Circulating Tumor Cells in Lung Adenocarcinoma: Implications of Test Results of Continuous Variables.
    Anticancer Res. 2020;40:7089-7094.
    PubMed     Abstract available

    November 2020
  121. NAGASHIMA T, Oshima T, Hiroshima Y, Yokose T, et al
    Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:6407-6416.
    PubMed     Abstract available

  122. SJOGREN K, Jacobsen KA, GrOnberg BH, Halvorsen TO, et al
    Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
    Anticancer Res. 2020;40:6399-6406.
    PubMed     Abstract available

  123. LEE SY, Slagle-Webb B, Sharma AK, Connor JR, et al
    Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment.
    Anticancer Res. 2020;40:6039-6049.
    PubMed     Abstract available

  124. HORIGUCHI H, Tsujimoto H, Shinomiya N, Matsumoto Y, et al
    A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation.
    Anticancer Res. 2020;40:6171-6178.
    PubMed     Abstract available

    October 2020
  125. CHEN HJ, Tu CY, Hsia TC, Fang HY, et al
    Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
    Anticancer Res. 2020;40:5895-5899.
    PubMed     Abstract available

  126. BASSO SMM, Del Conte A, Zuccon U, Sulfaro SC, et al
    Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion.
    Anticancer Res. 2020;40:5877-5881.
    PubMed     Abstract available

  127. YAMADA Y, Tamura T, Yamamoto Y, Ichimura H, et al
    Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
    Anticancer Res. 2020;40:5757-5764.
    PubMed     Abstract available

  128. BALBINOTTI H, Cadore NA, Dutra CS, DA Silva ED, et al
    Protein Profiling of Extracellular Vesicles Associated With Cisplatin Resistance in Lung Cancer.
    Anticancer Res. 2020;40:5509-5516.
    PubMed     Abstract available

  129. HAAG A, Jayakrishnan T, Shah D, Sandhu A, et al
    First Reported Case of Localized Extra-pulmonary Small Cell Carcinoma (EPSC) of the Esophagus Treated With Triple Therapy.
    Anticancer Res. 2020;40:5919-5923.
    PubMed     Abstract available

  130. SIMONI N, Micera R, Rossi G, Giri MG, et al
    Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
    Anticancer Res. 2020;40:5901-5907.
    PubMed     Abstract available

  131. MANOHARAN A, Lugo-Baruqui A, Ciancio G
    Radical Nephrectomy and Pulmonary Lobectomy for Renal Cell Carcinoma With Tumor Thrombus Extension into the Inferior Vena Cava and Pulmonary Arteries.
    Anticancer Res. 2020;40:5837-5844.
    PubMed     Abstract available

  132. KITAHARA H, Okamoto T, Shimamatsu S, Kohno M, et al
    LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma.
    Anticancer Res. 2020;40:5659-5666.
    PubMed     Abstract available

  133. SONODA T, Yanagitani N, Suga K, Yoshizawa T, et al
    A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.
    Anticancer Res. 2020;40:5577-5582.
    PubMed     Abstract available

  134. GERGEN AK, Kohtz PD, Halpern AL, Li A, et al
    Activation of Toll-Like Receptor 2 Promotes Proliferation of Human Lung Adenocarcinoma Cells.
    Anticancer Res. 2020;40:5361-5369.
    PubMed     Abstract available

    September 2020
  135. KOBAYASHI K, Kaira K, Kagamu H
    Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.
    Anticancer Res. 2020;40:5309-5311.
    PubMed     Abstract available

  136. NONPANYA N, Prakhongcheep O, Petsri K, Jitjaicham C, et al
    Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells.
    Anticancer Res. 2020;40:4989-4999.
    PubMed     Abstract available

  137. CHEN HL, Gong JY, Lin SC, Li S, et al
    Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies.
    Anticancer Res. 2020;40:4947-4960.
    PubMed     Abstract available

  138. FLESCHUTZ K, Walter L, Leistner R, Heinzerling L, et al
    ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4937-4946.
    PubMed     Abstract available

  139. HALLEY A, Leonetti A, Gregori A, Tiseo M, et al
    The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer.
    Anticancer Res. 2020;40:4807-4818.
    PubMed     Abstract available

  140. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed     Abstract available

    August 2020
  141. NAKAO T, Okuda T, Yoshioka H, Fujita M, et al
    Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4801-4804.
    PubMed     Abstract available

  142. TAKAHASHI Y, Soh J, Shien K, Yamamoto H, et al
    Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients.
    Anticancer Res. 2020;40:4419-4423.
    PubMed     Abstract available

  143. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer.
    Anticancer Res. 2020;40:4327-4330.
    PubMed     Abstract available

  144. TAKEUCHI A, Oguri T, Fukuda S, Sone K, et al
    Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4245-4251.
    PubMed     Abstract available

  145. TAMIYA A, Tamiya M, Go H, Inoue T, et al
    A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4229-4236.
    PubMed     Abstract available

  146. CZAJKA M, Zajkowska A, Gawlak M, Bujalska-Zadrozny M, et al
    Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung.
    Anticancer Res. 2020;40:4425-4444.
    PubMed     Abstract available

  147. CAO C, Kong MX, Kapali M, Moezardalan K, et al
    EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
    Anticancer Res. 2020;40:4401-4404.
    PubMed     Abstract available

    July 2020
  148. HOHNECK A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, et al
    Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm.
    Anticancer Res. 2020;40:4137-4145.
    PubMed     Abstract available

  149. UEDA Y, Suzuki O, Ohira S, Yagi M, et al
    The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.
    Anticancer Res. 2020;40:4095-4104.
    PubMed     Abstract available

  150. TOMITA M, Maeda R, Ayabe T, Nakamura K, et al
    Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4023-4027.
    PubMed     Abstract available

  151. NODA Y, Suzuki H, Kanai T, Samejima Y, et al
    The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.
    Anticancer Res. 2020;40:3931-3937.
    PubMed     Abstract available

  152. KUBO S, Kobayashi N, Somekawa K, Hirata M, et al
    Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.
    Anticancer Res. 2020;40:3889-3896.
    PubMed     Abstract available

  153. ORYWAL K, Jelski W, KozLowski MD, Mroczko B, et al
    Activity of Alcohol Dehydrogenase and Aldehyde Dehydrogenase in Lung Cancer Cells.
    Anticancer Res. 2020;40:3857-3863.
    PubMed     Abstract available

    June 2020
  154. ABE T, Kobayashi N, Aoshika T, Ryuno Y, et al
    Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy.
    Anticancer Res. 2020;40:3513-3517.
    PubMed     Abstract available

  155. BAXA J, Ludvik J, Sedlmair M, Flohr T, et al
    Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination.
    Anticancer Res. 2020;40:3459-3468.
    PubMed     Abstract available

  156. MOON SM, Kim JH, Kim SK, Kim S, et al
    Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Anticancer Res. 2020;40:3435-3444.
    PubMed     Abstract available

  157. TAKAHASHI K, Menju T, Nishikawa S, Miyata R, et al
    Tranilast Inhibits TGF-beta1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines.
    Anticancer Res. 2020;40:3287-3296.
    PubMed     Abstract available

  158. KIM B, Kim SW, Lim JY, Park SJ, et al
    NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2020;40:3239-3246.
    PubMed     Abstract available

  159. SP N, Kang DY, Kim DH, Yoo JS, et al
    Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis.
    Anticancer Res. 2020;40:3209-3220.
    PubMed     Abstract available

  160. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed     Abstract available

  161. PALUMBO B, Capozzi R, Bianconi F, Fravolini ML, et al
    Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With (18)F-FDG-PET/CT.
    Anticancer Res. 2020;40:3355-3360.
    PubMed     Abstract available

    May 2020
  162. YOSHIDA H, Kim YH, Sakamori Y, Nagai H, et al
    A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2981-2987.
    PubMed     Abstract available

  163. RADES D, Nguyen T, Khoa MT, Janssen S, et al
    Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2847-2851.
    PubMed     Abstract available

  164. KANAI T, Suzuki H, Yoshida H, Matsushita A, et al
    Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:2787-2793.
    PubMed     Abstract available

  165. MIYAUCHI S, Shien K, Takeda T, Araki K, et al
    Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Anticancer Res. 2020;40:2667-2673.
    PubMed     Abstract available

  166. SRIRATANASAK N, Nonpanya N, Wattanathana W, Chanvorachote P, et al
    Benzoxazine Dimer Analogue Targets Integrin beta3 in Lung Cancer Cells and Suppresses Anoikis Resistance and Migration.
    Anticancer Res. 2020;40:2583-2589.
    PubMed     Abstract available

  167. LEE TG, Kim SY, Kim HR, Kim H, et al
    Radiation Induces Autophagy via Histone H4 Lysine 20 Trimethylation in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2020;40:2537-2548.
    PubMed     Abstract available

  168. SHIBATA MA, Shibata E, Morimoto J, Kondo Y, et al
    Urethane-induced Mammary Carcinogenesis Susceptibility in Transgenic Mice Expressing a Dominant-negative TGF-beta Type II Receptor.
    Anticancer Res. 2020;40:2687-2694.
    PubMed     Abstract available

  169. AOKI M, Ueda K, Umehara T, Kamimura GO, et al
    Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma.
    Anticancer Res. 2020;40:2911-2916.
    PubMed     Abstract available

    April 2020
  170. TONE M, Inomata M, Awano N, Kuse N, et al
    Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Anticancer Res. 2020;40:2239-2246.
    PubMed     Abstract available

  171. SVATON M, Zemanova M, Zemanova P, Kultan J, et al
    Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2209-2217.
    PubMed     Abstract available

  172. MOUNTZIOS G, Mavropoulou X, Koliou GA, Linardou H, et al
    Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group.
    Anticancer Res. 2020;40:2095-2106.
    PubMed     Abstract available

  173. KIM DH, Sp N, Kang DY, Jo ES, et al
    Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G2/M Cell-cycle Arrest and Intrinsic Cell Death Pathway.
    Anticancer Res. 2020;40:1905-1913.
    PubMed     Abstract available

  174. YAN L, Rust BM, Picklo MJ
    Plasma Metabolomic Changes in Mice With Time-restricted Feeding-attenuated Spontaneous Metastasis of Lewis Lung Carcinoma.
    Anticancer Res. 2020;40:1833-1841.
    PubMed     Abstract available

  175. YAMAMOTO T, Niibe Y, Matsumoto Y, Dekura Y, et al
    Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors.
    Anticancer Res. 2020;40:2065-2072.
    PubMed     Abstract available

  176. TU YN, Tong WL, Callahan BM, Chobrutskiy BI, et al
    B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate.
    Anticancer Res. 2020;40:2043-2051.
    PubMed     Abstract available

  177. ZHAO S, Guo X, Taniguchi M, Kondo K, et al
    Detection of Mediastinal Lymph Node Metastases Using Indocyanine Green (ICG) Fluorescence Imaging in an Orthotopic Implantation Model.
    Anticancer Res. 2020;40:1875-1882.
    PubMed     Abstract available

  178. SHUKUYA T, Oyanagi J, Serizawa M, Watanabe M, et al
    Hypoxia Inducible Factor-1alpha Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2020;40:1867-1874.
    PubMed     Abstract available

  179. LUU TT, Bach DH, Kim D, Hu R, et al
    Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
    Anticancer Res. 2020;40:1855-1866.
    PubMed     Abstract available

  180. HOFFMANN M, Reitz D, Taugner J, Roengvoraphoj O, et al
    Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:2319-2322.
    PubMed     Abstract available

  181. SCHALLIER D, Lesfevre P, Everaert H
    Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report.
    Anticancer Res. 2020;40:2265-2269.
    PubMed     Abstract available

  182. SIMETIC L, Blazicevic K, Medugorac K, Golcic M, et al
    Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Anticancer Res. 2020;40:2157-2163.
    PubMed     Abstract available

    March 2020
  183. LIU Y, Huber RM, Kiefl R, Tufman A, et al
    Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells.
    Anticancer Res. 2020;40:1451-1458.
    PubMed     Abstract available

  184. DURAN-MORENO J, Kokkali S, Ramfidis V, Salomidou M, et al
    Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.
    Anticancer Res. 2020;40:1697-1703.
    PubMed     Abstract available

  185. ARSHI J, Sauer M, Yin F
    Rapid Sarcomatoid Transformation of Lung Squamous Cell Carcinoma After Neoadjuvant Therapy: A Case Report.
    Anticancer Res. 2020;40:1625-1629.
    PubMed     Abstract available

  186. IMAI H, Kaira K, Naruse I, Kasahara N, et al
    Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Anticancer Res. 2020;40:1571-1578.
    PubMed     Abstract available

  187. SAKATA KI, Maeda K, Sakurai N, Liang S, et al
    ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
    Anticancer Res. 2020;40:1307-1314.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.